PT KALBE FARMA TBK

PT KALBE FARMA TBK

Previous company name

Name change date

Company Overview
PT Kalbe Farma Tbk is the leading pharmaceutical company in Indonesia. It is engaged in the production and distribution of pharmaceutical products in Indonesia and abroad. The company was established in 1966 and its head office is located in Jakarta, Indonesia.
Kalbe Farma comprises four divisions that include: pharmaceuticals – provides a range of licensed and generic ethical products that cover various therapeutic categories, including cancers, renal disease, cardiac diseases, and brain trauma, to hospitals, general practitioners, specialist physicians, pharmacies, and government agencies; consumer foods – include over-the-counter (OTC) drugs comprising cough remedies, multivitamins, acne creams, energy drinks, nutritional products, infant foods, clinical foods for pregnant women and diabetics, and powdered milks for babies, toddlers, and children; packaging – supplies flexible and paper packaging solutions for drugs, cosmetics, and nutrition products; and distribution – markets its products in Indonesia, Malaysia, Vietnam, the Philippines, Thailand, Myanmar, Sri Lanka, and South Africa.
The company also develops new drugs and chemical entities as well as various therapeutic categories either by itself or in alliance with international strategic partners, including BioGaia AB, Danstar Ferment AG, Emcure, and Sinclair. In addition, the company has a joint venture with Orange Drugs Co., Ltd. to manufacture OTC products in Nigeria; with Morinaga Milk Industry to engage in nutrition business; and with Cordlife International Pte., Ltd. to provide umbilical cord banking services.
The company aims to become a player in the global market with strong brands, enhanced by excellent management and cutting-edge technology.
Business Summary
The Company is engaged in the development, production and distribution of pharmaceutical products for human and animals.
Description and history
On September 10 1966, coinciding in the year of the birth of the ‘ Orde Baru’ (New Order) administration in Indonesia, a pharmaceutical company was founded and named Kalbe Farma. The undertaking started its operation in a modest garage at Simpang Street I No.1 Tanjung Priok, North Jakarta. The desire to fulfill the people’s need for medicines combined with a pulsating entrepreneurial spirit were the driving forces behind the venture.

The Company is engaged in the development, production and distribution of pharmaceutical products for human and animals. It has four core business segments, namely prescription pharmaceutical, consumer health, nutritionals, and distribution and packaging. The products under the Health division include energy drink, nutrition and over-the-counter products.

The first year was marked by determined efforts to develop the necessary competences. However, guided by the spirit of helping people to achieve better health and a higher qualify of life, as well as reflected by the company’s motto: ‘ The Scientific Pursuit of Health for a Better Life’, Kalbe eventually managed to overcome all early difficulties and has since emerged as one of Indonesia’s leading pharmaceutical companies.

Kalbe initially entered the market with a single product named BIOPLACENTON, a topical skin treatment produced at the Company’s modest formulation facility, which up to this day has been able to perform satisfactorily.

In 1997 Kalbe Farma moved to Cikarang with 100,000 square meters in Delta Silicon Industrial Area at Jalan M.H Thamrin A3-1.

In January 1991, as part of the corporate restructuring of the Kalbe Farma Group prior to Kalbe Farma’s initial public offering, Kalbe Farma acquired the entire share capital pf Helios from Enseval.

In June 1993, recognizing the potential for significant operating and marketing synergies, Helios acquired the entire share capital of BMS which was 100% beneficially owned by Enseval. With this acquisition, the Group rationalized Helios, BMS, and SHP under one management team to take advantage of these synergies more effectively. Collectively, the Food Companies are referred to Kalbe Farma as Helios Foods.

After divestment of confectionery and biscuit business in 1996 and 1997, Kalbe focuses on health food business through PT Sanghiang Perkasa.

In 1998, Kalbe Farma acquired a 74.5% interest in Igar Jaya. Igar Jaya believed that its products, which are primarily targeted at the medical profession, complemented Kalbe Farma increased its interest in Igar Jaya to 100% in April 1990, and subsequently arranged a public offer and listing on the Indonesian Stock Exchanges of Igar Jaya shares in September 1990. At present, approximately 20% of the issued share capital of Igar Jaya were held by the public.

In October 1991, as part of the corporate restructuring of the Kalbe Farma Group prior to Kalbe Farma’s initial public offering, Kalbe Farma acquired shares in Avesta from Enseval. The acquisition was made to secure a captive supply of high quality packaging materials for the Group’s products.

Kalbe Farma now controls approximately 12.8% of all pharmaceutical sales in Indonesia. To penetrate the international market, Kalbe established five marketing representative offices in Sri Lanka, Malaysia, Vietnam, Myanmar, and South Africa. Exports to those countries generate about 9% of the consolidated annual sales of Kalbe Farma.

Business Line
Engaged in the production and distribution of pharmaceutical products
Subsidiary
CHAMPION PACIFIC INDONESIA TBK
Advisor
PURWANTONO, SARWOKO & SANDJAJA
IPO date
7/30/1991
US SIC Code
2834
Company Address
KALBE BUILDING
JL. LETJEND. SUPRAPTO KAV. 4,
City province or state postal code
10510, JAKARTA
Phone: +62 21 4287 3888
Fax: +62 21 4287 3680
Country address: INDONESIA
Website url: www.kalbefarma.com

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>